GCB-001 in Treatment of Patients With Type II (SMA) Spinal Muscular Atrophy

NAEnrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions

Spinal Muscular Atrophy Type 2

Interventions

GENETIC

GCB-001

GCB-001 is a self-complementary AAV9 carrying a full length human SMN transgenetic product.

Trial Locations (1)

Children's Hospital ZheJiang Univisity School Of Medicine, Hangzhou

All Listed Sponsors

collaborator

The Children's Hospital of Zhejiang University School of Medicine

OTHER

lead

Genecombio Ltd.

OTHER

NCT06772402 - GCB-001 in Treatment of Patients With Type II (SMA) Spinal Muscular Atrophy | Biotech Hunter | Biotech Hunter